Jim Simons Revolution Medicines, Inc. Transaction History

Renaissance Technologies LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$20.76 - $30.09 $898,908 - $1.3 Million	43,300 New	43,300 $938,000
Q3 2022 Nov 14, 2022	BUY	$17.46 - $26.0 $1.2 Million - $1.79 Million	68,900 New	68,900 $1.36 Million
Q1 2022 May 13, 2022	SELL	$17.31 - $26.4 $953,780 - $1.45 Million	-55,100 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$24.35 - $33.7 $1.34 Million - $1.86 Million	55,100 New	55,100 $1.39 Million
Q3 2021 Nov 12, 2021	SELL	$23.95 - $33.41 $548,455 - $765,088	-22,900 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$29.0 - $47.44 $385,700 - $630,952	13,300 Added 138.54%	22,900 $727,000
Q1 2021 May 13, 2021	BUY	$37.21 - $54.43 $357,216 - $522,528	9,600 New	9,600 $440,000

266

161M

260K

620K

Ticker RVMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,697,600
Market Cap $3.86B
Description
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.